Supreme Court Rules Narrowly Against Medicare Payments Cuts To 340B Hospitals
Executive Summary
The decision doesn’t directly impact manufacturers or the 340B discounts they are required to provide – and does not address the potentially much broader regulatory issue of whether the Supreme Court’s so-called Chevron doctrine should be changed.
You may also be interested in...
340B Dispute Resolution Decisions Subject To Administrative Appeal Under Proposal
US Health and Human Services Department revises approach to 340B administrative dispute resolution process and presiding panel in proposed rule.
US Supreme Court’s EPA Ruling Expected To Have Limited Impact On FDA Regulations
Court restricts EPA’s ability to regulate greenhouse gas emissions saying agency must have “clear congressional authorization” to address “major questions.” Decision is not likely to pose a problem for the FDA unless it were to regulate something new, attorneys say.
Drug Pricing Day At The US Supreme Court
Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.